ANI Pharmaceuticals, Inc. (ANIP) vs Kestra Medical Technologies, Ltd. (KMTS)
A side-by-side comparison of ANI Pharmaceuticals, Inc. and Kestra Medical Technologies, Ltd. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ANIP
ANI Pharmaceuticals, Inc.
$71.23HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
KMTS
Kestra Medical Technologies, Ltd.
$27.37HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
Total return — ANIP vs KMTS
growth of $100 · dividends reinvested · last 2yANIP +21.6% (+10.3%/yr)KMTS +29.8% (+13.9%/yr)KMTS compounded faster over this window
ANIP KMTS
ANIP vs KMTS: by the numbers
- •ANIP is the larger company ($1.62B vs $1.60B market cap).
- •ANIP is profitable (10.82% net margin) while KMTS runs a net loss (-140.43%).
Metrics side by side
Valuation
| Metric | ANIP | KMTS |
|---|---|---|
| P/E ratio | 15.38 | N/A |
| Forward P/E | 7.68 | N/A |
| P/S ratio | 1.66 | 15.03 |
| P/B ratio | 2.71 | 7.21 |
| EV / EBITDA | 6.74 | N/A |
Profitability
| Metric | ANIP | KMTS |
|---|---|---|
| Gross margin | 51.01% | 53.89% |
| Operating margin | 15.35% | -134.48% |
| Net margin | 10.82% | -140.43% |
| ROE | 17.72% | -67.40% |
| ROIC | 9.26% | -47.99% |
Growth (annualized)
| Metric | ANIP | KMTS |
|---|---|---|
| Revenue CAGR (5Y) | 35.61% | N/A |
| Total return CAGR (5Y) | 16.86% | N/A |
Frequently asked
- Is ANIP or KMTS more profitable?
- ANIP runs the higher net margin — ANIP at 10.82% versus KMTS at -140.43%.
Go deeper
Dig into the metrics
ANI Pharmaceuticals P/E ratioANI Pharmaceuticals ROEKestra Medical Technologies ROEANI Pharmaceuticals operating marginKestra Medical Technologies operating marginANI Pharmaceuticals revenue growthKestra Medical Technologies revenue growthANI Pharmaceuticals free cash flowKestra Medical Technologies free cash flow
ANI Pharmaceuticals & Kestra Medical Technologies appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.